FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1037 April 13, 1995 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: The clinical benefit of vancomycin, useful for over 30 years in the treatment of patients infected with gram-positive bacteria, has recently been compromised by the development of resistance — especially by enterococci.¹ The Centers for Disease Control and Prevention (CDC) have drafted guidelines for the judicious use of vancomycin in an effort to minimize selection for these strains.² We are concerned that Medicare reimbursement policies may result in increased use of vancomycin.

As the largest national purchaser of health care, the Medicare program can profoundly influence health care delivery through its reimbursement policies. Medicare does not routinely . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.